Antibody therapeutics that bind CD38

Patent metadata

Field	Value
Publication number	US-11999792-B2
Application number	US-202017016104-A
Country	US
Kind code	B2
Filing date	Sep 9, 2020
Priority date	Apr 8, 2015
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

First claim

We claim:

1. One or more nucleic acids encoding an antibody of an IgG class that binds to a CD38 epitope, wherein said antibody comprises
(i) a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 3; and
a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 4; or
(ii) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 3 and a light chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 4.

2. The one or more nucleic acids of claim 1 , wherein said antibody comprises the heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 3 and the light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 4.

3. The one or more nucleic acids of claim 1 , wherein the antibody is an IgG1 antibody.

4. The one or more nucleic acids of claim 1 , wherein the antibody is an IgG4 antibody.

5. The one or more nucleic acids of claim 1 , wherein the antibody is a full-length antibody.

6. The one or more nucleic acids of claim 1 , wherein the antibody is an antibody fragment or single chain antibody comprising the heavy chain variable domain sequence and the light chain variable domain sequence.

7. The one or more nucleic acids of claim 6 , wherein the antibody fragment or single chain antibody is a Fab or F(ab')2 fragment or an scFv.

8. The one or more nucleic acids of claim 1 , wherein the antibody binds CD38 with a binding affinity of at least 10 −6 M.

9. The one or more nucleic acids of claim 1 , wherein the antibody binds CD38 with a binding affinity of at least 10 −8 M.

10. The one or more nucleic acids of claim 2 , wherein the antibody is an IgG1 antibody.

11. The one or more nucleic acids of claim 2 , wherein the antibody is an antibody fragment or single chain antibody comprising the heavy chain variable domain sequence and the light chain variable domain sequence.

12. The one or more nucleic acids of claim 2 , wherein the antibody is an IgG4 antibody.

13. The one or more nucleic acids of claim 2 , wherein the antibody binds CD38 with a binding affinity of at least 10 −6 M.

14. The one or more nucleic acids of claim 2 , wherein the antibody binds CD38 with a binding affinity of at least 10 −8 M.

15. The one or more nucleic acids of claim 1 , wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence that is at least 95% identical to SEQ ID NO: 3, a light chain variable domain comprising the amino acid sequence that is at least 95% identical to SEQ ID NO: 4, three heavy chain complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO: 3, and three light chain CDRs as set forth in the light chain variable domain amino acid sequence of SEQ ID NO: 4.

16. One or more vectors comprising the one or more nucleic acids of claim 1 .

17. A host cell comprising the one or more nucleic acids of claim 1 .

18. A host cell comprising the one or more vectors of claim 16 .

19. A method of producing an antibody, comprising culturing the cell of claim 17 under conditions wherein the antibody is produced.

20. A method of producing an antibody, comprising culturing the cell of claim 18 under conditions wherein the antibody is produced.

Assignees

• Sorrento Therapeutics Inc
• Vivasor Inc

Inventors

• Zhou Heyue
• Gray John Dixon

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K16/2896 Primary

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title

• C07K16/40

  against enzymes · CPC title